Stryker Corporation (SYK) : 21 analysts are covering Stryker Corporation (SYK) and their average rating on the stock is 1.83, which is read as a Buy. 13 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Stryker Corporation (SYK) also receives 2 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 2 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Stryker Corporation (SYK) has been rated by 16 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $138 and the lowest price target forecast is $88. The average forecast of all the analysts is $125.38 and the expected standard deviation is $11.67.
For the current week, the company shares have a recommendation consensus of Buy. Also, Guggenheim Securities initiates coverage on Stryker Corporation (NYSE:SYK). Guggenheim Securities has a Buy rating on the shares. The rating by the firm was issued on June 9, 2016.
Stryker Corporation (NYSE:SYK): stock was range-bound between the intraday low of $114.85 and the intraday high of $116.8 after having opened at $116.44 on Wednesdays session. The stock finally closed in the red at $116.44, a loss of -1.47%. The stock remained in the red for the whole trading day. The total traded volume was 1,202,026 shares. The stock failed to cross $116.8 in Wednesdays trading. The stocks closing price on Thursday was $116.89.
Stryker Corporation is a medical technology company. The Company offers a range of products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine, which help improve patient and hospital outcomes.